A Use for Geldanamycin and Derivatives as Inhibitors of TGFB Signaling and Extracellular Matrix Synthesis

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:		00-40
IP Type:		Licensable Technology
Title:		A Use for Geldanamycin and Derivatives as Inhibitors of TGFB Signaling and Extracellular Matrix Synthesis
Inventor:		Strehlow, David
Summary:		The invention is the discovery of a new use for an existing drug being developed by the NCI for other indications. The drug inhibits the production of collagen. Its usefulness is thus in inhibiting disease states which are pathogenic because of the overproduction of collagen. These diseases include scleroderma, keloid, and other fibrotic diseases of the liver, lungs, kidney, and other internal organs or skin.
Tech Type:		Therapeutics - Methods
URL:		http://ctf-fmfe.bu.edu/BU0040.pdf
Contact:		Rick T. Clark, rclark@bu.edu, 617 358 4208
Organization:		Boston University

Display all intellectual properties for Strehlow, David
Display all intellectual properties for Boston University